NCT03645434 - A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

August 7, 2019

Study Completion Date

August 7, 2019

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

AZD8871

Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.

DRUG

Anoro® Ellipta®

Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.

Trial Locations (5)

Research Site, Berlin

Research Site, Grosshansdof

Research Site, Wiesbaden

Research Site, London

Research Site, Manchester